Upexi Fiscal 2023 Revenue Increases 250% Year-Over-Year to $80.7 Million and Provides Revenue Guidance Range for Fiscal 2023 First Quarter
- Revenue guidance for Q1 2023 is $26-27 million
- Revenue for FY2023 increased 250% YoY to $80.7 million
- Gross profit increased 126% to $33.6 million
- Adjusted EBITDA for FY2023 was $1.27 million
- Tytan Tiles plans to launch new products and signed a licensing agreement with Disney
- LuckyTail expands product line
- Net loss for FY2023 was $16.9 million
- Sales and marketing expenses increased to $10.4 million
- Distribution costs increased to $12.4 million
- General and administrative expenses increased to $9.5 million
- Other operating expenses totaled $8.8 million
Management provides revenue guidance range for fiscal 2023 first quarter of
TAMPA, FL / ACCESSWIRE / October 2, 2023 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal year ending June 30, 2023.
"Revenue growth year-over-year was predominately driven by the performance of our leading brands, VitaMetica, Lucky Tail and Tytan Tiles, as well as our re-commerce business. Even as we continue to integrate the operations of our acquisitions and reduced non-acquisition operating expenses by
Financial Highlights for the Fiscal Year Ending June 30, 2023:
- Revenue totaled
$80.7 million , an increase of250% year-over-year, as compared to$23.1 million year-over-year. - Gross profit totaled
$33.6 million , an increase of126% , as compared to$14.9 million year-over-year. - Gross profit margins were
41.6% as compared to64.5% for the prior year period. - Adjusted EBITDA totaled
$1.27 million as compared to an adjusted EBITDA loss of$(4.1) for the same period in the prior year. - Net loss attributable to Upexi, Inc. shareholders was
$16.9 million as compared to a net loss of approximately$2.1 million for the same period last year. - As of June 30, 2023, cash and cash equivalents totaled
$4.5 million , working capital of$5.8 million and availability on the line of credit of over$6 million . On September 30, 2023, the Company had availability of over$9.8 million on the line of credit.
Operational Highlights for 2023:
$1.9 million reduction in operational expenses.- In August 2022, Upexi acquired E-Core, Inc and its subsidiaries, New England Technology, Inc. (NETi), a company specializing in re-commerce of overstocked and discontinued merchandise for hundreds of retailers, and Tytan Tiles, a children's educational toy brand.
- Tytan Tiles exceeded sales expectations during initial 2,200 store launch and will increase its rollout of the brand to over 3,900 stores through the second half of 2023.
- Tytan Tiles officially approved by Amazon.com to launch its first branded DTC storefront, Tytan Brands Store.
- Tytan Tiles plans to launch up to four new products in 2023, including, Magnetic Cubes, Fort Builder Kit, Dino Tiles Kit and Princess Titles Kit through its retail network and Amazon.
- Acquired the remaining
45% interest in Cygnet Online, an Amazon and eCommerce seller with 1,200 active SKUs of branded OTC products. - Tytan Tiles signed licensing agreement with The Walt Disney Company to launch brands such as Frozen, The Lion King, Toy Story, Cars and many others on Amazon, DTC and into Upexi's big box retail channels during the 2023 holiday season.
- Announced the development of an AI engine to analyze purchasing, advertising, customer buying habits, times, demographics and other data collected in partnership with SME Solutions Group, Inc.
- Upexi sold Interactive Offers for
$1.25 million , subject to customer post-closing adjustments, and a2.5% royalty obligation on certain advertising revenue for a two-year period post-closing. - LuckyTail expands product line with the launch of all-natural dog supplements.
Financial Results for the Fiscal Year Ending June 30, 2023:
Revenue totaled
Cost of revenue totaled
Sales and marketing expenses totaled
Distribution costs totaled
General and administrative expenses increased to
Other operating expenses totaled
Other expenses increased by
Adjusted EBITDA for fiscal 2023 totaled
The Company had a net loss of
On June 30, 2023, the Company had cash of
As of today, October 2, 2023, there are 20,397,779 shares of common stock outstanding.
Financial Results Conference Call
| Event: | Fiscal 2023 Full Year Financial Results Conference Call |
| Date: | Monday, October 2, 2023 |
| Time: | 4:30 p.m. Eastern Time |
| Live Call: | 1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International) |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1634526&tp_key=7536fca2fa |
For those unable to join the conference call, a dial-in replay of the call will be available until October 16, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13741232. Additional details are available under the Investor Relations section of the Company's website: https://upexi.com/investors .
About Upexi, Inc.:
Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current database has been key to the year over year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house, SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.
FORWARD LOOKING STATEMENTS:
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
| Reconciliation of Non-GAAP Adjusted EBITDA to GAAP Net Income (Net Loss) Year Ended June 30, | |||||||||
| 2023 | 2022 | ||||||||
Net income (Net loss) GAAP | $ | (16,930,289 | ) | $ | (2,100,850 | ) | |||
Income tax | (3,049,293 | ) | (518,398 | ) | |||||
Interest expense, net | 4,761,903 | 202,120 | |||||||
Depreciation and amortization | 5,153,695 | 1,554,297 | |||||||
Stock compensation | 3,664,538 | 3,331,586 | |||||||
Loss on the sale of Infusionz and select assets | 2,212,542 | - | |||||||
Change in derivative liability | (1,770 | ) | 3,293 | ||||||
Loss (gain) on discontinued operations | 2,068,054 | (3,823,621 | ) | ||||||
Gain on SBA PPP loan forgiveness | - | (300,995 | ) | ||||||
(Loss) income attributable to non-controlling interest | (559,967 | ) | 54,820 | ||||||
Lease impairment, California facility | 200,512 | - | |||||||
Gain on sale of asset | - | (5,500 | ) | ||||||
Impairment of Intangible assets | 3,746,301 | - | |||||||
Non-GAAP adjusted EBITDA | $ | 1,266,226 | $ | (1,603,248 | ) | ||||
Use of Non-GAAP Financial Measures
The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to establish operational goals, for compensation plans, to measure debt service capability, for capital expenditure planning and to determine working capital needs and believes that these are useful financial measures also used by investors. Non-GAAP adjusted EBITDA is defined as GAAP net income or net loss before interest, taxes, depreciation and amortization (EBITDA) adjusted for the non-cash stock compensation and stock option expense, acquisition, integration & restructuring expenses, charges and gains or losses from extinguishment of debt and other non-cash items. Non-GAAP EBITDA and non-GAAP adjusted EBITDA are not terms defined by GAAP and, as a result, the Company's measure of non-GAAP EBITDA and non-GAAP adjusted EBITDA might not be comparable to similarly titled measures used by other companies. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position, or cash flow that either excludes or includes amounts that are not normally included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP financial measures discussed above, however, should be considered in addition to, and not as a substitute for, or superior to net income or net loss as reported for GAAP on the Consolidated Statements of Operations, cash and cash flows on the Consolidated Statement of Cash Flows or other measures of financial performance prepared in accordance with GAAP, and as reflected on the Company's financial statements prepared in accordance with GAAP. These non-GAAP financial measures are not a substitute for or presented in lieu of financial measures provided by GAAP and all measures and disclosures of financial information pursuant to GAAP should be read to obtain a comprehensive and thorough understanding of the Company's financial results. The reconciliations of non-GAAP EBITDA and non-GAAP adjusted EBITDA to GAAP operating income (loss) and/or GAAP net income (net loss) referred to in the highlights or elsewhere are provided in the schedules that are a part of this document.
Company Contact
Andrew Norstrud, Chief Financial Officer
Email: andrew.norstrud@upexi.com
Phone: (702) 332-5591
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
Email: Upexi@KCSA.com
Phone: (212) 896-1254
UPEXI, INC.
CONDENSED CONSOLIDIATED BALANCE SHEETS
| June 30, | June 30, | |||||||
| 2023 | 2022 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash | $ | 4,492,291 | $ | 7,149,806 | ||||
Accounts receivable | 7,163,564 | 939,875 | ||||||
Inventory | 11,557,128 | 4,725,685 | ||||||
Due from Bloomios | 845,443 | - | ||||||
Deferred tax asset, current | - | 462,070 | ||||||
Prepaid expenses and other receivables | 1,307,299 | 760,900 | ||||||
Current assets of discontinued operations | 89,989 | 3,023,286 | ||||||
Total current assets | 25,455,714 | 17,061,622 | ||||||
Property and equipment, net | 7,526,463 | 7,338,866 | ||||||
Intangible assets, net | 13,571,960 | 8,755,012 | ||||||
Goodwill | 10,251,281 | 4,644,609 | ||||||
Deferred tax asset | 5,604,056 | 2,002,759 | ||||||
Investments - Bloomios | - | - | ||||||
Other assets | 96,728 | 75,613 | ||||||
Assets held for sale | 936,054 | 7,767,698 | ||||||
Right-of-use asset | 410,811 | 844,856 | ||||||
Total other assets | 38,397,353 | 31,429,413 | ||||||
Total assets | $ | 63,853,067 | $ | 48,491,035 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 3,969,746 | $ | 1,572,275 | ||||
Accrued compensation | 533,842 | 489,712 | ||||||
Deferred revenue | - | - | ||||||
Accrued liabilities | 3,365,562 | 816,632 | ||||||
Acquisition payable | - | - | ||||||
Current portion of notes payable | 2,731,377 | 749,752 | ||||||
Current portion of convertible notes payable | 1,254,167 | 3,125,000 | ||||||
Current portion of acquisition note payable | 5,656,620 | 1,550,000 | ||||||
Line of Credit | 882,845 | - | ||||||
Current portion of operating lease payable | 419,443 | 183,881 | ||||||
Current liabilities of discontinued operations | 792,408 | 1,640,496 | ||||||
Total current liabilities | 19,606,010 | 10,127,748 | ||||||
Operating lease payable, net of current portion | 163,359 | 700,411 | ||||||
Convertible notes payable | 895,833 | 3,180,406 | ||||||
Acquisition notes payable, net of current | 7,605,085 | - | ||||||
Notes payable, net of current portion | 7,746,157 | 5,695,726 | ||||||
Total long-term liabilities | 16,410,434 | 9,576,543 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity | ||||||||
Preferred stock, | 500 | 500 | ||||||
Common stock, | 20,216 | 16,713 | ||||||
Additional paid in capital | 51,522,229 | 34,985,597 | ||||||
Accumulated deficit | (23,201,175 | ) | (6,270,886 | ) | ||||
Total stockholders' equity attributable to Upexi, Inc. | 28,341,770 | 28,731,924 | ||||||
Non-controlling interest in subsidiary | (505,147 | ) | 54,820 | |||||
Total stockholders'' equity | 27,836,623 | 28,786,744 | ||||||
Total liabilities and stockholders' equity | $ | 63,853,067 | $ | 48,491,035 | ||||
UPEXI, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Year Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
Revenue | ||||||||
Revenue | $ | 80,676,509 | $ | 23,065,344 | ||||
Cost of Revenue | 47,118,189 | 8,195,735 | ||||||
Gross profit | 33,558,320 | 14,869,609 | ||||||
Operating expenses | ||||||||
Sales and marketing | 10,376,003 | 5,116,868 | ||||||
Distribution costs | 12,369,903 | 2,214,322 | ||||||
General and administrative expenses | 9,546,188 | 9,141,667 | ||||||
Share-based compensation | 3,664,538 | 3,331,586 | ||||||
Amortization of acquired intangible assets | 4,208,991 | 979,988 | ||||||
Depreciation | 944,704 | 574,309 | ||||||
| 41,110,327 | 21,358,740 | |||||||
Loss from operations | (7,552,007 | ) | (6,489,131 | ) | ||||
Other income (expense), net | ||||||||
Interest (expense) income, net | (4,761,903 | ) | (202,120 | ) | ||||
Change in derivative liability | 1,770 | (3,293 | ) | |||||
Loss on sale of Infusionz and select assets | (2,212,542 | ) | - | |||||
Impairment of Interactive Offers intangible assets | (3,746,301 | ) | - | |||||
Gain on sale of property and equipment | - | 5,500 | ||||||
Lease impairment, California facility | (200,512 | ) | - | |||||
Gain on SBA PPP loan extinguishment | - | 300,995 | ||||||
Other (expense) income, net | (10,919,488 | ) | 101,082 | |||||
Net loss before income tax | (18,471,495 | ) | (6,388,049 | ) | ||||
Income tax benefit | 3,049,293 | 518,398 | ||||||
Net loss from continuing operations | (15,422,202 | ) | (5,869,651 | ) | ||||
(Loss) income from discontinued operations - Interactive Offers | (1,729,636 | ) | (1,160,160 | ) | ||||
(Loss) income from discontinued operations - Infusionz | (338,418 | ) | 4,983,781 | |||||
Net loss (income) attributable to non-controlling interest | 559,967 | (54,820 | ) | |||||
Net (loss) income attributable to Upexi, Inc. | $ | (16,930,289 | ) | $ | (2,100,850 | ) | ||
Basic income (loss) per share: | ||||||||
Loss per share from continuing operations | $ | (0.86 | ) | $ | (0.36 | ) | ||
Income per share from discontinued operations | $ | (0.10 | ) | $ | (0.07 | ) | ||
Total income (loss) per share | $ | (0.96 | ) | $ | (0.43 | ) | ||
Diluted income (loss) per share: | ||||||||
Loss per share from continuing operations | $ | (0.86 | ) | $ | (0.36 | ) | ||
Income per share from discontinued operations | $ | (0.10 | ) | $ | (0.07 | ) | ||
Total income (loss) per share | $ | (0.96 | ) | $ | (0.43 | ) | ||
Basic weighted average shares outstanding | 17,877,959 | 16,224,520 | ||||||
Fully diluted weighted average shares outstanding | 17,877,959 | 16,224,520 | ||||||
UPEXI, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended June 30, | ||||||||
| 2023 | 2022 | |||||||
Cash flows from operating activities | ||||||||
Net (loss) income from operations | $ | (16,930,289 | ) | $ | (2,100,850 | ) | ||
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 5,153,695 | 2,733,455 | ||||||
Non-cash loss on the sale of Infusionz and select assets, net | 2,212,542 | - | ||||||
Gain on forgiveness of PPP loan | - | (300,995 | ) | |||||
Gain on sale of assets | - | (5,500 | ) | |||||
Inventory write-offs | 118,990 | 1,044,607 | ||||||
Bad debt expense | - | 131,968 | ||||||
Amortization of consideration discount | 969,098 | - | ||||||
Amortization of senior security original issue discount | 62,408 | - | ||||||
Impairment of goodwill and intangible assets | 3,746,301 | - | ||||||
Non-controlling interest | (559,967 | ) | 54,820 | |||||
Change in deferred tax asset | (3,139,227 | ) | (1,061,238 | ) | ||||
Shares issued for services | - | 576,774 | ||||||
Shares issued for finder fee | 1,770 | - | ||||||
Stock based compensation | 3,664,538 | 2,755,016 | ||||||
Changes in assets and liabilities, net of acquired amounts | ||||||||
Accounts receivable | 476,256 | 284,998 | ||||||
Inventory | 1,260,479 | (2,795,486 | ) | |||||
Prepaid expenses and other assets | 168,499 | 284,653 | ||||||
Operating lease payable | 132,555 | 37,922 | ||||||
Accounts payable and accrued liabilities | 3,180,049 | (446,609 | ) | |||||
Deferred revenue | - | (478,385 | ) | |||||
Net cash provided by operating activities - Continuing Operations | 517,697 | 715,150 | ||||||
Net cash used in operating activities - Discontinued Operations | (315,021 | ) | (895,981 | ) | ||||
Net cash provided by operating activities | 202,676 | (180,831 | ) | |||||
Cash flows from investing activities | ||||||||
Acquisition of Lucky Tail | (3,528,239 | ) | - | |||||
Acquisition of VitaMedica, Inc., net of cash acquired | (500,000 | ) | (2,574,589 | ) | ||||
Acquisition of New England Technology, Inc. | (2,051,587 | ) | - | |||||
Acquisition of Cygnet | (1,050,000 | ) | (1,028,763 | ) | ||||
Acquisition of Interactive Offers, net of cash acquired | - | (1,854,193 | ) | |||||
Proceeds from the sale of Infusionz and selected assets | 5,492,532 | |||||||
Acquisition of property and equipment | (937,564 | ) | (5,451,773 | ) | ||||
Proceeds from the sale of equipment | 6,000 | |||||||
Net cash used in investing activities - Continuing Operations | (2,574,858 | ) | (10,903,318 | ) | ||||
Net cash (used in) provided by investing activities - Discontinued Operations | - | - | ||||||
Net cash used in investing activities | (2,574,858 | ) | (10,903,318 | ) | ||||
Cash flows from financing activities | ||||||||
Repayment of notes payable | (445,670 | ) | (852,874 | ) | ||||
Repayment of SBA note payable | (305,482 | ) | - | |||||
Repayment of the senior convertible notes payable | (6,305,406 | ) | - | |||||
Proceeds of the senior convertible notes payable | - | 6,678,506 | ||||||
Payment on line of credit, net | (6,318,234 | ) | - | |||||
Repayment of notes payable | - | (150,000 | ) | |||||
Proceeds on note payable on building | 3,000,000 | - | ||||||
Proceeds from the issuance of stock, net | 6,127,893 | |||||||
Stock repurchase program | - | (1,975,888 | ) | |||||
Repayment on note payable on building | (158,434 | ) | - | |||||
Proceeds from issuance of convertible debt | 2,650,000 | |||||||
Proceeds on note payable, related party | 1,470,000 | - | ||||||
Net cash used in financing activities - Continuing Operations | (285,333 | ) | 3,699,744 | |||||
Net cash (used in) provided by financing activities - Discontinued Operations | - | - | ||||||
Net cash used in financing activities | (285,333 | ) | 3,699,744 | |||||
Net decrease in cash - Continuing Operations | (2,342,494 | ) | (6,488,424 | ) | ||||
Net decrease in cash - Discontinued Operations | (315,021 | ) | (895,981 | ) | ||||
Cash, beginning of year | 7,149,806 | 14,534,211 | ||||||
Cash, end of year | $ | 4,492,291 | $ | 7,149,806 | ||||
Supplemental cash flow disclosures | ||||||||
Interest paid | $ | 2,278,292 | $ | 64,460 | ||||
Income tax paid | $ | - | $ | 656,000 | ||||
Non-cash financing activities | ||||||||
Issuance of common stock for acquisition of Infusionz | $ | - | $ | 1,764,876 | ||||
Issuance of common stock for acquisition of VitaMedica | $ | - | $ | 482,000 | ||||
Issuance of debt for acquisition of VitaMedica | $ | - | $ | (309,574 | ) | |||
Issuance of common stock for interest expenses | $ | 607,004 | $ | - | ||||
Issuance of common stock for services | $ | 140,700 | $ | 140,700 | ||||
Issuance of common stock for acquisition of E-Core | $ | 6,000,000 | $ | - | ||||
Liabilities assumed from acquisition of E-Core | $ | (7,712,168 | ) | $ | - | |||
Operating assets designated as held for sale | $ | 1,026,043 | $ | 10,790,984 | ||||
Liabilities assumed from acquisition of VitaMedica | $ | - | $ | (309,574 | ) | |||
Issuance of stock for acquisition of Interactive | $ | - | $ | 2,733,628 | ||||
Liabilities assumed from acquisition of Cygnet | $ | - | $ | 9,472,438 | ||||
SOURCE: Upexi, Inc.
View source version on accesswire.com:
https://www.accesswire.com/789293/upexi-fiscal-2023-revenue-increases-250-year-over-year-to-807-million-and-provides-revenue-guidance-range-for-fiscal-2023-first-quarter
